Lysteda



Tranexamix Acid (LYSTEDA)

Product Specs Tranexamix Acid (LYSTEDA)
Manufacturer Name Ferring
Indications Tranexamic acid, USP, is an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding.
Contraindications Not for use in patients with congenital factor XIII B-subunit Deficiency. Hypersensitivity to the active substance or to any of the excipients.
Manufacturing Methods Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine with antifibrinolytic properties.
Viral Safety Process Chromatography steps, including hydrophobic interaction and ion exchange chromatography
Route of Administration Oral or intravenous administration
Product Half-Life 11.08 ± 1.9 hours
Storage Requirements/Shelf Life
  • Store at room temperature at 25°C (77°F)
  • Excursions permitted to 15-30°C (59-86°F)
  • Do not use beyond expiration date on label.
    		•
    Available Formulations 650 mg tablets
    100 mg/mL for intravenous injection


    Return to Manufacturer Name listing Return to Factor Type listing